The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma | ||
| dc.conicet.organizacion | Massachusetts General Hospital | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos | |
| dc.conicet.organizacion | Inserm | |
| dc.conicet.organizacion | Harvard Medical School. Department of Medicine. Massachusetts General Hospital | |
| dc.conicet.organizacion | Harvard Medical School. Department of Medicine. Massachusetts General Hospital | |
| dc.conicet.organizacion | Harvard Medical School. Department of Medicine. Massachusetts General Hospital | |
| dc.conicet.organizacion | Inserm | |
| dc.contributor.author | Bolm, Louisa | |
| dc.contributor.author | Fraunhoffer Navarro, Nicolas Alejandro | |
| dc.contributor.author | Dusetti, Nelson Javier | |
| dc.contributor.author | Straesser, Julia | |
| dc.contributor.author | Petruch, Natalie | |
| dc.contributor.author | Fernandez del Castillo, Carlos | |
| dc.contributor.author | Iovanna, Juan Lucio | |
| dc.date.issued | 2025-05 | |
| dc.description.abstract | Introduction: In the current study, we aimed to assess the efficacy of a gemcitabine response predictive signature that is part of the PancreasView transcriptomic predictive tool (Gem + or Gem−). Methods: We used a cohort of pancreatic ductal adenocarcinoma patients treated from the Massachusetts General Hospital who underwent upfront resection. Results: In this cohort of 43 patients, 20 (46.5%) received adjuvant gemcitabine (GEM arm) and 23 (53.5%) did not receive any adjuvant chemotherapy. Among the 43 patients, the Gem signature defined a subgroup of 16 patients (37.2%) who were sensitive (Gem+) and 27 (62.8%), who were resistant to gemcitabine (Gem−). The Gem+ patients who received adjuvant gemcitabine had significantly better median disease-free survival (DFS) compared to the Gem− patients (NR until 72 months of follow-up vs 19.0 months; stratified hazard ratio [HR]: 0.19; 95% CI, 0.04- 0.86; P = .032) and longer median cancer-specific survival (CSS) (NR until 96 months of follow-up vs 37.0 months; stratified HR: 0.18; 95% CI, 0.04-0.85; P = .030) when treated with gemcitabine. The gemcitabine signature remained an independent predictive factor for DFS (HR: 0.41; 95% CI, 0.19-0.89; P = .024) and CSS (HR: 0.47; 95% CI, 0.22-1.23; P = .059) after adjusting for clinicopathological characteristics in an unstratified univariate Cox hazard model. Conclusions: This validation of the gemcitabine predictive transcriptomic signature in an independent cohort from Massachusetts General Hospital reinforces the robustness and reliability of this tool. This study highlights the potential of the signature to aid in the personalization of chemotherapy and enhance patient outcomes in pancreatic ductal adenocarcinoma. | es |
| dc.description.fil | Fil: Bolm, Louisa. Massachusetts General Hospital; Estados Unidos | |
| dc.description.fil | Fil: Fraunhoffer Navarro, Nicolas Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina | |
| dc.description.fil | Fil: Dusetti, Nelson Javier. Inserm; Francia | |
| dc.description.fil | Fil: Straesser, Julia. Harvard Medical School. Department of Medicine. Massachusetts General Hospital; Estados Unidos | |
| dc.description.fil | Fil: Petruch, Natalie. Harvard Medical School. Department of Medicine. Massachusetts General Hospital; Estados Unidos | |
| dc.description.fil | Fil: Fernandez del Castillo, Carlos. Harvard Medical School. Department of Medicine. Massachusetts General Hospital; Estados Unidos | |
| dc.description.fil | Fil: Iovanna, Juan Lucio. Inserm; Francia | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Bolm, Louisa; Fraunhoffer Navarro, Nicolas Alejandro; Dusetti, Nelson Javier; Straesser, Julia; Petruch, Natalie; et al.; The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma; Alphamed Press; The Oncologist.; 30; 5; 5-2025; 1-5 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1083-7159 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/291273 | |
| dc.journal.number | 5 | es |
| dc.journal.pagination | 1-5 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | The Oncologist. | es |
| dc.journal.volume | 30 | es |
| dc.language.iso | eng | es |
| dc.publisher | Alphamed Press | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/oncolo/article/30/5/oyaf083/8128446?login=false | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1093/oncolo/oyaf083 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | PANCREATIC CANCER | es |
| dc.subject | GEMCITABINE | es |
| dc.subject | SIGNATURE | es |
| dc.subject.classification | Patología | es |
| dc.subject.classification | Medicina Básica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.dad5773f-056c-49f2-8a44-1457c419bf9d_Ñ.pdf
- Tamaño:
- 503.55 KB
- Formato:
- Adobe Portable Document Format
- Descripción: